Clinical Trials on L-MYC and N-MYC Amplified Solid Tumors in Australia
Total 3 results
-
Ascendis Pharma Oncology Division A/SRecruitingAdvanced Solid Tumor | Metastatic Solid Tumor | Platinum-resistant Ovarian Cancer | Locally Advanced Solid Tumor | Post Anti-PD-1 Melanoma | 2L+ Cervical Cancer | Neoadjuvant Melanoma | Neoadjuvant Non-Small Cell Lung Cancer | Post Anti-PD-(L)1 Non-Small Cell Lung Cancer | Post Anti-PD-(L)1 Small Cell...United States, Australia, Korea, Republic of
-
AstraZenecaDaiichi Sankyo Co., Ltd.Active, not recruitingPart 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer | Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal CancerBelgium, United States, Poland, India, Taiwan, Thailand, Korea, Republic of, Czechia, Russian Federation, United Kingdom, Spain, Australia, Canada, Italy, Netherlands
-
Incyte CorporationActive, not recruitingCervical Cancer | Nasopharyngeal Carcinoma | Mesothelioma | Advanced Solid Tumor | Small-cell Lung Cancer | Esophageal Squamous Cell Carcinoma | Urothelial Carcinoma | Merkel Cell Carcinoma | HepatoCellular Carcinoma | Cutaneous Squamous Cell Carcinoma | MSI-H/dMMR Tumors | PD-L1 Amplified Tumor (9p24.1)France, United States, Japan, Belgium, Australia